Scenic Biotech to work with NIH

Country

Netherlands

Scenic Biotech BV of the Netherlands is to work with a unit of the US National Institutes of Health to advance its therapeutic programme for the treatment of Niemann-Pick Type C (NPC) disease, a severe, progressive neurological disorder. Scenic is developing a small molecule compound for the disorder by identifying genetic modifiers. These are naturally occurring genes that compensate for mutations that are responsible for severe diseases. The goal of the collaboration is to get clinical insight into genes that might reduce the severity of NPC in patients.